⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S3 from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors

Anthony W. Tolcher Joshua Brody Nishanthan Rajakumaraswamy Michelle Kuhne Torsten Trowe Anees M. Dauki Shantheri Pai Ling Han Kai-Wen Lin Michael Petrarca Shivaani Kummar

View Full Paper

Ask AI

Bookmark

Share

Abstract

Concentration vs. time profiles of GS-3583. Mean ± standard deviation GS-3583 serum concentration vs. time profile in patients with solid tumors. A. Log-linear scale; B. Linear scale. The lower limit of quantification was 5 ng/mL.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tolcher et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db6435875226e4 https://doi.org/10.1158/1078-0432.27034465

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S3 from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors2024
2Supplementary Figure S2 from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors2024
3Supplementary Figure S2 from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors2024
4Supplementary Figure S4 from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors2024
5Supplementary Figure S4 from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors2024